- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02584543
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) Coadministration With Recombinant Hepatitis B Vaccine
This is a open label, randomized phase VI study, to assess the safety and immunogenicity of co-administration of Hepatitis E vaccine with Hepatitis B vaccine. The concomitant group (n =300) received Hepatitis B vaccine concomitantly with Hepatitis E vaccine at day 1 and months 1 and 6; The nonconcomitant group (n =150) received Hepatitis E vaccine at at day 1 and months 1 and 6. Another nonconcomitant group (n=150) received Hepatitis B vaccine at at day 1 and months 1 and 6.
Anti-HEV IgG and HBsAb were determined. Injection-site and systemic adverse events (AEs) were monitored for 30 days after any vaccination; serious AEs were monitored throughout the study.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina
- Beijing Chaoyang District CDC
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Healthy people aged over 18 years old on the day of enrollment
- Negative in HBsAg,HBsAb and HBcAb.
- Judged as healthy and eligible for vaccination by the investigators through a selfreported medical history and some physical examinations.
- Able to understand this study information and willing to comply with all study requirements.
- Willing to participate in this study and sign informed consent form.
Exclusion Criteria:
- Pregnant or breastfeeding or planning on getting pregnant in the future 7 months
- Use of any investigational product or non-registered product (drug or vaccine)within 30 days preceding the first dose of the study vaccine or plan to use during the study period
- Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, exceptlocal treatment.
- Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine,or plan to use during the study period.
- Administration of any inactivated vaccines within 14 days preceding the first dose of the study or attenuated live vaccines within 21 days preceding the first dose of the study.
- Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring systemic antibiotics or antiviral treatment within 5 days before vaccination.
- Plan to participate in any other clinical trial during the study period
- Administration of HEV vaccine before the study.
- Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor,or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response).
- History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy,urticaria, dyspnea, angioneurotic edema or abdominal pain.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: HEV vaccine and HBV vaccine Co-administration group
|
|
Aktiv komparator: HEV vaccine control group
|
|
Aktiv komparator: HBV vaccine control group
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Adverse reactions/events
Tidsramme: 7 months
|
Measure solicited local adverse reactions within 7 days after each vaccination; Measure solicited systematic adverse reactions within 7 days after each vaccination; Measure unsolicited adverse reactions within 30 days after vaccination; Measure serious adverse events occurred throughout the study
|
7 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Immunogenicity
Tidsramme: 7 months
|
Measure anti-HEV antibody in serum samples at 7 month to evaluate the immunogenicity of the Hepatitis E vaccine.
And measure the HBsAb in serum samples at 7 month to evaluate the immunogenicity of Hepatitis B vaccine.
|
7 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Zheng Zhang, Beijing Chaoyang District CDC
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Leversygdomme
- Hepatitis, viral, menneskelig
- Hepadnaviridae infektioner
- DNA-virusinfektioner
- Gram-negative bakterielle infektioner
- Bakterielle infektioner
- Bakterielle infektioner og mykoser
- Enterovirus infektioner
- Picornaviridae infektioner
- Enterobacteriaceae infektioner
- Hepatitis B
- Hepatitis
- Hepatitis A
- Escherichia coli infektioner
- Hepatitis E
- Lægemidlers fysiologiske virkninger
- Immunologiske faktorer
- Vacciner
Andre undersøgelses-id-numre
- PRO-HE-007
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesIkke rekrutterer endnu
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UkendtKronisk hepatitis b
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu... og andre samarbejdspartnereRekrutteringKronisk hepatitis b | Reaktivering af hepatitis BTaiwan
-
Mahidol UniversityUkendtKronisk Hepatitis B, HBsAg, Hepatitis B-vaccineThailand
-
Tongji HospitalGilead SciencesRekruttering
-
Jiangsu HengRui Medicine Co., Ltd.Ukendt
-
Changhai HospitalAfsluttet
-
Brii Biosciences LimitedVir Biotechnology, Inc.Aktiv, ikke rekrutterendeKronisk hepatitis B-virusinfektionSingapore, Thailand, Australien, Kina, Korea, Republikken
-
Nanfang Hospital of Southern Medical UniversityRekruttering
-
IlDong Pharmaceutical Co LtdRekrutteringKronisk hepatitis bKorea, Republikken
Kliniske forsøg med HEV vaccine
-
Central Hospital, Nancy, FranceUkendt
-
National Institute of Allergy and Infectious Diseases...Afsluttet
-
Maisonneuve-Rosemont HospitalRekruttering
-
University Hospital OstravaRekruttering
-
Mahmoud Abdel RahmanAssiut UniversityUkendt
-
Johnson & Johnson Vision Care, Inc.RekrutteringSynsstyrkeForenede Stater
-
TASK Applied ScienceAfsluttet
-
Norwegian Institute of Public HealthInternational Centre for Diarrhoeal Disease Research, Bangladesh; Sykehuset...AfsluttetHepatitis E infektionBangladesh
-
Xiamen UniversityMinistry of Science and Technology of the People´s Republic of China; Xiamen... og andre samarbejdspartnereAfsluttetLivmoderhalskræft | Cervikal intraepitelial neoplasi | Vaginal intraepitelial neoplasi | Vulvar intraepitelial neoplasi | Vedvarende infektionKina
-
Southwest Oncology GroupNational Cancer Institute (NCI)AfsluttetHoved- og halskræftForenede Stater